

Clarification

The purpose of this presentation is to present the activity of Sonovia Ltd. ("hereinafter: the "Company") and to provide initial and basic information only about its activity. The presentation does not constitute an investment proposal or proposal to acquire Company's securities and in particular it does not constitute a "public offering" or "sale to the public" of any kind and nature whatsoever. Offering or sale as aforesaid, if any, shall be made based on prospectus published by the Company subject to the prior authorization of the Securities Authority and the approval of the Tel Aviv Stock Exchange, Ltd.

This presentation does not purport to include all information which may be relevant for the purpose of making any decision to invest in Company's securities and in general. Investment in securities in general, and in Company's securities in particular, carries risks. It should be taken into consideration that past data are not necessarily indicative of future performance. The presentation includes statistical and other data and publications published by third parties, the content of which has not been examined by the Company, and the Company is not responsible for their accuracy.

This presentation was designed for overview and convenience only. It does not exhaust all data regarding the Company and its activity and does not replace the need to inspect the prospectus which shall be published by the Company after receiving the authorization of the Securities Authority and the approval of the Tel Aviv Stock Exchange, Ltd., if and to the extent published. Nothing stated in this presentation constitutes consultation of any kind (including tax or business consultation) and it does not come *in lieu* of consultation with qualified consultants in these areas. All potential investors should obtain consultation and guidance in connection with potential investments, including tax consultation considering their data and tax status and circumstances.

This presentation includes, *inter alia*, forward-looking information, as defined in the Securities Law, 5728-1968, including forecasts, goals, business strategy, estimates and assessments concerning Company's activity and the markets in which it operates, and any other information, in any form presented, referring to future events and/or matters whose realization is neither guaranteed nor in Company's control. Said information is based, *inter alia*, on current estimates and forecasts of Company's management based on information available to the Company at the time of this presentation, which although the Company believes to be reasonable, is uncertain by its nature and is partially based on subjective estimates only. The realization or non-realization of forward-looking information shall be affected, *inter alia*, by risk factors characterizing Company's activities, as well as by decisions of third parties including regulatory bodies, developments in the economic environment and external factors affecting Company's activities, which may not be predicted and are not under Company's control. In addition, any reference in this presentation to Company's goals and strategy is limited to the publication date of this presentation. Said goals may change from time to time according to the resolutions of the Company's authorized organs. The Company does not undertake to update and/or amend any forecast and/or estimate as aforesaid and does not undertake to amend or update this presentation.

ABOUT THE COMPANY

Sonovia was established in 2013 for the commercialization of two Bar-Ilan University patents which had been approved for innovation in the area of anti-bacterial fabric coating.

The commercialization of the knowledge was made following the completion of an R&D project led by Bar-Ilan research team. The project received Euro 8.3 million in funding from the European Union. Sonovia's technology is used for:



Upon the Cov-19 outbreak the **Company embarked** on the manufacturing and sale of antibacterial and antiviral face masks

As of September 30, 2020, the Company generated more than USD 5 million* in revenues and reached profitability.



Reducing the use of polluting chemicals



Development of additional applications such as water repellence and fire retardancy

Durable Antibacterial and antiviral coating for textiles [99% effective against Cov-19]








OUR TEAM

Sonovia's leadership team consists of leading experts in the areas of management, chemistry, engineering, textile, business development and strategy, who led the Company to substantial technological and business accomplishments.



















OUR VISION



Leading the global fight against epidemics and acquired infections alongside the development and commercialization of advanced applications for the textile industry.




Sonovia's ground breaking technology provides an environmental friendly alternative for advanced applicative textile treatments.














TECHNOLOGIES FOR PERFORMING APPLICATIVE TEXTILE TREATMENTS

Technology Description	Regular soaking	Synthetic fiber	Plasma Treatment	Sono-chemical Soaking
Durability to industrial laundry	NO	YES	NO	HIGH
Durability to home laundry	MEDIUM	YES	MEDIUM	MEDIUM
Applicability to all types of textile	NO	NO	NO	YES
Cost-benefit	HIGH	LOW	LOW	HIGH
Environmental pollution and Personal infection	HIGH	HIGH	LOW	LOW





THE PROBLEM: ACQUIRED INFECTIONS IN HOSPITALS



In the US and Europe alone,

each year millions of patients hospitalized in medical institutions are infected by deadly bacteria and about **200,000 of them die.**



In the US and Europe alone,

the annual economic damage to healthcare systems incurred as a result of Hospital Acquired Infections is estimated at about **US\$80 Billion**, and together with the damage to the economy It is estimated at about **US\$160 Billion**.



Textile surfaces are easily contaminated by bacteria and viruses.

Currently there is no technologically and commercially viable solution for this problem in the hospital market.



THE PROBLEM: ENVIRONMENTAL POLLUTION AND PERSONAL INFECTION



Applicative textile treatments are responsible for 20% of global water pollution.

Textiles contaminate about 9 trillion gallons of water every year.



The increasing awareness among textile consumers throughout the world leads to a sharp increase in the scope of regulation and

additional enforcement by world leading brands



The market of applicative treatments which is estimated at about USD 15 Billion is expected to be required by regulation and market forces to adopt green technologies









THE PROBLEM: LIVING DURING AND AFTER COV-19




As a result of the Cov-19
outbreak, an immediate need
arose for surface coating
technologies actively and
effectively extinguishing viruses
and bacteria to protect the public
and prevent infection



Public awareness and consciousness leads to new market competition – which company shall provide its customers with the best protection from infections



Markets which have not yet widely assimilated purification technologies, currently act actively and strategically to adopt advanced purification technologies








Sonovia: high resistance, 99% effective against viruses [including Covid-19] and bacteria




00000

THE TECHNOLOGY


Ultrasound waves artificially create high-energy cavitation bubbles forcing, when collapsed, the desired particles into the textile by a water shock-waves








THE BUSINESS MODEL – HP MODEL





OUR POSITION WITHIN THE VALUE CHAIN



*The presented companies are examples and presented for illustration purposes only. As of the date of the presentation, Sonovia Ltd. Is not affiliated in any way with any of the companies presented and is not entitled in any way to the trademarks presented in this presentation.

ACCOMPLISHMENTS

2018

The Company entered into a strategic R&D agreement with the leading textile machinery corporation Bruckner Textile Machinery



2018

The Company was selected to join the world leading textile industry Fashion for Good start-up accelerator, which in addition has invested USD 230 thousand in the Company





2019

The Company received a non-diluting, partner-free grant in the sum of Euro 2.4 million* from the European Comission SME Program



Horizon 2020 European Union funding for Research & Innovation

2020


Technology was proven effective against Cov-19; Pilots with world leading automotive and fashion corporations; sales in excess of USD 5 million** and reaching profitability.







STATUS, DEVELOPMENT PLANS AND **COMMERCIALIZATION FORECAST**


























TARGET MARKET SIZE – SUMMARY

Sonovia's revenue potential, in terms of sale prices



Total market size - \$16.2 Billion

The figures presented above in accordance with the chemical formulations market prices



PRODUCTS DIVISION

In March 2020, two months after the outbreak of the Cov-19 virus, Sonovia identified an opportunity to check the market demand for the company's anti-bacterial/anti-viral application in the private market and started manufacturing branded face masks.



As of September 30, 2020, Sonovia's sales exceeded USD 5 Million* with high gross profitability. The Company expects demand for protective masks in the western world to remain stable in the foreseeable future



The Products Division proves the attractiveness of the technology and Sonovia's brand with end- consumers in the western world. Additional products shall be added in the future to increase the scope of sales.



The Products Division shall conduct, in relevant instances, market validation for Sonovia's future products and shall validate market demand before launching wide-scoped commercialization efforts.



SONOVIA - IN THE MEDIA







TAGS: Sonovia EU Horizon 2020







color costoners frazes

261 OFMARKET PEN